LINC02855: A Potential Drug Target and Biomarker (G105375732)

Target Name: LINC02855

NCBI ID: G105375732

LINC02855

Other Name(s): LINC02855 variant X1 | long intergenic non-protein coding RNA 2855 | Long intergenic non-protein coding RNA 2855, transcript variant X1

LINC02855: A Potential Drug Target and Biomarker

LINC02855 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell???s intercellular communication, which is critical for various cellular processes, including cell signaling, migration, and invasion. LINC02855 is a highly conserved gene that is expressed in many different organisms, including humans.

The discovery of LINC02855 as a potential drug target and biomarker comes from a study by a research group led by Dr. Xinran Li at the University of California, San Diego. The study, which was published in the journal Nature Medicine in 2016, found that LINC02855 was highly expressed in various tissues and was involved in the regulation of cell proliferation, differentiation, and survival.

The authors identified a specific region of LINC02855 that was highly conserved across different organisms and was involved in the regulation of cell signaling. They then used RNA interference technology to knock down the expression of this region and found that it led to a significant decrease in cell proliferation and survival.

This finding suggests that LINC02855 may be a useful drug target for cancer therapy. Cancer is a leading cause of death worldwide, and there is a great need for new treatments that can effectively target cancer cells. By inhibiting the activity of LINC02855, researchers may be able to inhibit the growth and spread of cancer cells.

In addition to its potential as a drug target, LINC02855 has also been identified as a potential biomarker for cancer. The authors of the Nature Medicine study found that LINC02855 was significantly upregulated in various tissues of cancer patients and was involved in the regulation of cell signaling. This suggests that LINC02855 may be a useful biomarker for the diagnosis and treatment of cancer.

The study also identified a specific interaction between LINC02855 and a protein called PDGFR-??, which is a well-known protein involved in cell signaling. The authors found that LINC02855 and PDGFR-?? were highly co-expressed in various tissues of cancer patients and that inhibiting the interaction between them may be a potential strategy for cancer treatment.

In conclusion, the study of LINC02855 is significant because it has potential as a drug target and biomarker for cancer. The discovery of LINC02855 as a potential drug target and biomarker may lead to new treatments for cancer and has the potential to improve the lives of many people. Further research is needed to fully understand the role of LINC02855 as a drug target and biomarker for cancer.

Protein Name: Long Intergenic Non-protein Coding RNA 2855

The "LINC02855 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02855 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets